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Background: Alpha 7 nicotinic acetylcholine receptors (α7 nAChR) are prioritized
molecular targets for the development of new pharmacological treatments for impaired
cognition in schizophrenia. The use of schizophrenia-associated biomarkers both as
endpoints and for segmentation of homogeneous populations for early detection of
cognitive enhancing agents has been advanced to enhance the drug discovery process.
Methods: In this study, the mismatch negativity (MMN) event-related brain potential
(ERP), considered one of the few fully developed biomarkers in schizophrenia, was
employed: a) to stratify 24 healthy volunteers into subgroups exhibiting low, medium,
or high auditory sensory discrimination based on pre-attentive detection of deviant
auditory features, and b) to assess their acute response to a low (500 mg) and moderate
dose (1000 mg) of CDP-choline, a dietary supplement with selective agonist actions at
α7 nAChRs.
Results: No significant whole group effects were observed with CDP-choline, and MMN
changes were observed only with analysis of subgroups. The effects of CDP-choline
interacted both with deviant type and auditory deviance detection level, with individuals
exhibiting low MMNs showing enhanced amplitudes, while those with high MMNs
evidenced reduced amplitudes with acute dosing of CDP-choline.
Conclusions: These preliminary findings of improved auditory deviance detection with
CDP-choline in our biomarker-defined healthy surrogate group supports the contention
that α7 nicotinic cholinergic agonism be studied as a potential pro-cognitive mechanism
in patients with schizophrenia.
Keywords: Alpha 7 nicotinic acetylcholine receptor, α7 nAChR, Nicotine, CDP-choline,
Event-related potential, ERP, Deviance detection, Mismatch negativity, MMN, SchizophreniaBackground
Nicotinic acetylcholine receptors (nAChR) have been implicated in cognitive function-
ing and preclinical studies have strongly supported attentional enhancing effects of ag-
onists acting at α7 and α4β2 nAChR subunits in the hippocampus and prefrontal
cortex (Bentley et al. 2011; dos Santos and Granon 2012; Levin et al. 2006; Mansvelder
et al. 2006; Sarter et al. 2009; Wallace and Bertrand 2013a, b). The prototypical nAChR© 2015 Knott et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
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reverse withdrawal-induced task performance impairments in smokers (Heishman et al.
1994) and has exerted positive effects in multiple cognitive domains, including motor
abilities, attention and memory, when administered in single “smoking doses” to non-
smokers (Heishman et al. 2010).
Smoking prevalence in schizophrenia (SZ), a disorder in which cognitive disturbances
are core features and are relatively nonresponsive to available antipsychotic treatments
(Gold 2004; Marder and Fenton 2004), ranges from 45 to 88%, compared to < 20% in
the general population (Dickerson et al. 2013; Morisano et al. 2013). Observed in ani-
mal models of SZ and in SZ patients, transient improvements in sensory, attentional,
mnemonic and executive functions with acute nicotine/nAChR agonist treatment
(D’Souza and Markou 2012; Kucinski et al. 2011; Leiser et al. 2009; Olincy and Freedman
2012; Radek et al. 2010) have collectively promoted the hypothesis of smoking in SZ as
self-medication for cognitive deficits mediated via nAChR pathophysiology (Kumari and
Postma 2005; Wing et al. 2012; Winterer 2010).
Converging lines of research have prioritized the α7 nAChR as one of the most
promising targets in the development of cognitive pharmacotherapies for patients with
SZ (Buchanan et al. 2007; Green 2007). Found both in SZ patients and their biological
relatives, a sensory gating deficit (inability to inhibit responses to redundant, irrelevant
stimuli) indexed by suppression of the auditory P50 event-related potential (ERP) has
shown genetic linkage to the locus on chromosome 15q13-14, which codes (i.e.,
CHRNA7) for the α7 nAChR subunit (Freedman et al. 1997; Raux et al. 2002). Possibly
reflecting single nucleotide changes within promoter regions of CHRNA7 (Leonard
et al. 2002), diminished numbers of apparently structurally intact α7 nAChRs have been
shown in the hippocampus (Freedman et al. 1995), frontal cortex (Guan et al. 1999)
and the nucleus reticularis thalami (Court et al. 1999) of SZ postmortem brains. Results
from clinical trials of novel α7 molecules in SZ patients have been mixed (Young and
Geyer 2013). DMXB-A (a.k.a. GTS-21), the first α7 partial agonist to be developed, evi-
denced pro-gating and pro-cognitive properties in an acute dosing paradigm (Olincy
et al. 2006) but failed to impact cognitive performance with chronic (4-weeks) treat-
ment (Freedman et al. 2008) and similar null effects were recently observed in an 8-
week study with the α7 nAChR partial agonist, RG3487 (Umbricht et al. 2014). This
contrasts with proof-of-concept trials with partial α7 agonists EVP-6124 (Hilt et al.
2011) and TC-5619 (Lieberman et al. 2013), both showing improved cognition in SZ
patients at week 12. Reviews of these and other α7 molecules under various stages of
clinical development have tentatively underscored the potential of α7 modulators as
add-on therapy to antipsychotics, but point to the need for a better understanding of
brain functions regulated by this receptor system (Bencherif et al. 2012; Geerts 2012;
Hurst et al. 2012; Wallace and Bertrand 2013a; Young and Geyer 2013).
Choline, an amine that is a precursor for the synthesis of acetylcholine, is an essential
nutrient that has many biological functions, and in addition to being a lipid component
involved in cell membrane protection and repair (Blusztajn 1998; Zeisel and Blusztujn
1994; Zeisel 2000) is a selective full agonist at the α7 nAChR (Albuquerque et al. 1998;
Alkondon et al. 1999; Fayuk and Yakel 2004). As gestational choline supplementation en-
hances gating and cognition in adult offspring mice (Meck and Williams 2003; Stevens
et al. 2008, 2014) and increases rates of efficient sensory inhibition (P50 suppression) in
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(Ross et al. 2013), dietary choline supplementation has been promoted as a possible pre-
ventive intervention for cognitive deficits in individuals considered to be “at risk” for SZ
(Corriveau and Glenn 2012; Freedman 2014).
Choline’s potential to address cognitive impairment associated with SZ has received
only minimal attention. 5’-citidine diphosphocholine or CDP-choline (citicoline) is a
dietary supplement which acts as a key intermediate in the biosynthesis of phosphat-
idylcholine from choline (Secades et al. 1995). CDP-choline has been shown to improve
impaired cognition associated with chronic ischaemia, head trauma, dementia and nor-
mal aging (Alvarez-Sabin and Roman 2011; Conant and Schauss 2004; Davalos et al.
2012; Fioravanti and Buckley 2006; Garcia-Cobos et al. 2010; Secades 2012). In a 16-
week trial combining CDP-choline with the positive allosteric modulator (PAM) of the
α7 and α4/β2 nAChRs, galantamine, clinical symptoms of SZ patients were unaffected
but overall functional level of patients was increased, as was performance on a test of
free verbal recall (Deutsch et al. 2013). CDP-choline in this study was administered in
the clinically recommended maximum dose range (2000 mg/day) but nAChR agonist
effects often display an inverted U-shaped dose response curve, with maximal effects
being observed at low and ultralow doses (Castner et al. 2011; Hahn et al. 2002;
Werkheiser et al. 2011).
The primary objective of this present study is to investigate the acute group-wise ef-
fects of low-to-moderate doses (500 mg, 1000 mg) of CDP-choline in a sample of
healthy volunteers. Prior to the implementation of costly and time consuming CDP-
choline clinical trials in patients, this study will employ a rationale strategy advocated
for the early identification of pro-cognitive drug actions, which involves the use of a
within-subject challenge dose design (placebo vs. active) in biomarker-identified sub-
groups (surrogate populations) that have only a limited symptom profile but without
the confounds (e.g. medication, disease chronicity, symptom variability) associated with
the disorder (Chou et al. 2012; Koychev et al. 2012). Cortical cholinergic input is re-
quired for normal auditory sensory and perceptual processing (Leach et al. 2013), defi-
cits of which are highly frequent in SZ and are indexed by ERP biomarkers (Javitt
2009). The mismatch negativity (MMN) ERP, which can probe dysfunction in basic per-
ceptual processes isolated to primary sensory regions and can be modeled in preclinical
studies, fulfills criteria for use as an endophenotypic marker (Gottesman and Gould
2003) of the SZ disease (Belger et al. 2012; Takahashi et al. 2013), and is considered
one of the few fully developed, “already mature” electrophysiologic biomarkers (Butler
et al. 2012; Green et al. 2009), allowing for unique opportunities for use as a transla-
tional biomarker in SZ drug discovery (Javitt et al. 2008). An essential feature of this
mature biomarker is its substantial test-retest reliability, which exceeds 0.8 in healthy
volunteers and patients and is of particular importance in clinical trials with repeated
measures designs (Light et al. 2012).
Auditory MMN, requiring no behavioural response or attention, is elicited as a fron-
tocentral maximum negative peak on the scalp (at ~ 120–250 ms) when a sequence of
repetitive stimuli is interrupted infrequently by deviant stimuli differing in any physical
or abstract manner. It is the earliest neural sign of acoustic change detection, and al-
though there are different explanations for the MMN (Fishman 2013; May and Tiitinin
2010), the “sensory memory” hypothesis proposes that it is an automatic, pre-attentive
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stimulus features in brief (lasting up to 30 sec) auditory (“echoic”) sensory memory
(Näätänen et al. 2011). Greater discrepancies between deviant and standard memory
traces (i.e., increasing deviance) are associated with larger MMN amplitudes and shorter
latencies, both measures being correlated with behavioural discrimination of sounds
(Näätänen et al. 2012). Frequently found in SZ (vs. bipolar disorder), deficits in MMN
generation are also observed in unaffected family members and first-episode patients
(Sumiyoshi et al. 2013; Nagai et al. 2013a, 2013b; Näätänen et al. 2014), and are exhibited
in patients in response to a variety of auditory deviants, although duration deviant MMNs
are viewed as being more trait specific for this disorder, while pitch and intensity deviant
MMNs have shown different temporal changes over the course of the illness (Näätänen
and Kahkonen 2008; Todd et al. 2008). Impaired MMN generation in SZ is linked to
structural (Rasser et al. 2011; Salisbury et al. 2007) and functional (Javitt 2000; Light and
Braff 2005) impairments in the auditory sensory cortex and correlates with negative symp-
toms and poor executive functioning (Kiang et al. 2007; Näätänen et al. 2004; Turetsky
et al. 2009; Umbricht et al. 2006) as well as deficits in social/occupational functioning
(Lee et al. 2014; Light and Braff 2005), while in healthy volunteers, the greater the MMN
amplitude, the stronger the functional status of the individual (Light et al. 2007).
MMN is relatively unaffected by antipsychotics, although we have shown it to correl-
ate with clozapine dose (Horton et al. 2011) which, among its other actions, indirectly
increases acetylcholine synaptic transmission (Ichikawa et al. 2002) and cortical glutam-
ate (Tanahashi et al. 2012). Strongly dependent on glutamatergic signaling, MMN is at-
tenuated in rats, monkeys and healthy adults with high-affinity NMDA (N-methyl-D-
aspartate)-type glutamate receptor antagonists (Javitt et al., 1996; Tikhonravov et al.
2008; Umbricht et al. 2000) such as ketamine which, when combined with nicotine,
fails to disrupt MMN in some (Knott et al. 2012) but not all investigations (Mathalon
et al. 2014). Most frequently investigated in healthy participants with frequency devi-
ants, nicotinic stimulation has resulted in negative (Knott et al. 2006, 2011), diminish-
ing (Knott et al. 2009) and enhancing effects on MMN amplitude (Dunbar et al. 2007),
with the latter positive outcome also being shown with pattern (Baldeweg et al. 2006),
temporal (Martin et al. 2009) and visual deviants (Fisher et al. 2010). Such response
variability is also seen in the relatively few studies in SZ, with nicotine not affecting fre-
quency deviant MMN (Dulude et al. 2010; Inami et al. 2007), shortening latency of
intensity-deviant MMN (Fisher et al. 2012) and in our work, “normalizing” duration-
deviant MMN by increasing the diminished MMN in patients to a level comparable to
that seen in healthy volunteers (Dulude et al. 2010).
Contributing to variability in MMN are individual difference in age (Ruzzoli et al. 2012),
intelligence (Bazana and Stelmack 2002), gender and personality (Matsubayashi et al.
2008). These factors, as well as genetic influences, and inter-subject differences in smoker
vs. nonsmoker status, pre-drug state, and functional level are also significant sources of in-
dividual variability in nicotine response (Gilbert and Gilbert 1995; Kupferschmidt et al.
2010; Li et al. 2009; Perkins 1995; Perkins 2009; Poltavski and Petros 2005). Frequently
shown in animal models and in human studies, baseline-dependent differences have influ-
enced behavioural, cognitive, and subjective mood responses to nicotine (Perkins 1999).
More recently, baseline-dependent neural responses to nicotine have been evidenced
with two widely used biomarkers of SZ, namely, P50-indexed auditory sensory gating
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2014), with both biomarkers being enhanced by acute nicotine, but only in individuals
with relatively diminished, SZ-like P50 gating and MMN baseline responses. In individuals
with high baseline gating and discriminability, P50 suppression and MMN amplitude were
either not affected, or were attenuated by single dose nicotine treatment. Only two reports
have examined the effects of α7 nAChR medications on MMN, both being conducted in
SZ patients. While JNJ-39393406, an α7 PAM, failed to alter MMN (Winterer et al. 2013),
the α7 partial agonist EVP-6124 increased the frequency deviant MMN in a dose-
dependent manner (Preskorn et al. 2014).
Taking advantage of demonstrated, biomarker-defined inter-individual heterogenecity
in sensory response to nicotinic receptor stimulation, this study will carry out an ex-
ploratory analysis on the possible relationship between endogenous choline and re-
sponse to CDP-choline by examining how individuals stratified on the basis of MMN
amplitude compare in their response to an acute low and moderate dose of CDP-
choline. In line with previous suggestions of an inverted U-shaped response character-
izing cognitive effects of nicotinic stimulation (Newhouse et al. 2004), and based on
our recent study with the prototypical nAChR agonist, nicotine, which enhanced audi-
tory deviance detection in individuals with small amplitude MMNs and attenuated de-
viance detection in those with higher amplitude MMNs (Knott et al. 2014), we
hypothesized that both doses of CDP-choline (vs. placebo) would increase deviance de-
tection (MMN) in individuals exhibiting relatively diminished detection ability (i.e. low
baseline MMN amplitudes) and exert negative or diminishing effects in those with rela-
tively moderate, optimal, or above optimal detection ability (i.e., medium or high base-
line MMN amplitudes). As the lower dose is likely to be associated with less α7
receptor desensitization, MMN enhancement is expected to be greater with 500 mg
(vs. 1000 mg) of CDP-choline. The study limited sample recruitment to healthy, young,
male adults with a non-smoking history in order to reduce other sources of inter-
individual variability.Methods
The study protocol was approved by the Research Ethics Boards of the Royal Ottawa
Health Care Group and the University of Ottawa and was carried out in accordance
with the Canadian Tri-Council Policy Statement for Ethical Conduct for Research In-
volving Humans. All volunteers provided written consent prior to participation and
were compensated $200 CAD for their time and effort.Participants
Recruited by advertisements, the study sample consisted of 24 healthy, right handed
males between 18–40 years of age. Volunteers were initially screened by telephone and
then by personal interview. Based on history and physical exam, all participants were
medically and neurologically normal and, as screened with the SCID-NP (Structured
Clinical Interview – Non-Patient version for DSM-IV: Williams et al. 1992) and FIGS
(Family Interview for Genetic Studies: Maxwell, 1992), had no personal or immediate
(first degree biological relatives) family history of psychiatric disorders. Participants
were nonsmokers, having smoked less than 100 cigarettes in their lifetime and none in
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consistent with a nonsmoker status (Cropsey et al. 2006). None of the participants re-
ported any use of smokeless tobacco products (e.g. nicotine gum or patch).Design
Participants were assessed in three separate sessions (placebo and two doses of CDP-
choline) within a randomized, double-blind, crossover design. Session order was coun-
terbalanced with respect to the total sample (not within each subgroup, which were
designated at study completion), so that the 6 possible randomization orders were re-
peated four times across 24 participants. Approximately 8–12 days separated the ses-
sions in order to allow for CDP-choline elimination.Procedure
Test sessions were conducted between 9:00 a.m. – 1:00 p.m., each following overnight ab-
stinence from smoking/nicotine, caffeine, alcohol, drugs/medication and food. Three
hours after treatment administration, the time of maximal drug absorption, ERPs were re-
corded following which, adverse events and vital signs were evaluated for safety purposes.CDP-choline
Participants were administered CDP-choline orally in two active doses, 500 mg (2 ×
250 mg capsules) and 1000 mg (4 × 250 mg capsules). In study trials, clinically effective
CDP-choline has been administered orally and by injection with doses ranging from
500 – 4000 mg/day, although generally efficacy has not substantially improved beyond
2000 mg/day. When administered orally, it is absorbed almost completely, with bio-
availability being 92 – 94% and approximately the same as when administered intraven-
ously (Agut et al. 1983). Single oral doses dose-dependently raise plasma levels and
increase brain choline levels, with peripheral levels rising slowly and peaking at 3 –
5 hr, and with elimination half-life extending up to 56 hr (Wurtman et al. 2000). In
studies with CDP-choline administered up to 12 months, it showed excellent tolerabil-
ity and safety, with a few transient (never severe) adverse effects (e.g. stomach pain,
diarrhea) (Conant et al. 2004; Fioravanti et al. 2006; Saver 2008). A “double dummy”
procedure was used with participants being administered 4 capsules in each session so
that the dose remained blind (e.g. 2 placebo capsules and 2 × 250 mg capsules com-
prised the 500 mg CDP-choline condition). The placebo capsules (containing cellulose)
physically matched the active capsules.Paradigm
During the MMN paradigm participants viewed a silent video (The Blue Planet by
BBC, 2001). In the optimal MMN paradigm (Näätänen et al. 2004), auditory tonal stim-
uli of 70 dB sound pressure level (SPL) were presented binaurally through headphones
and consisted of standard (p = 0.5) stimuli (composed of 500, 1000, and 1500 Hz pure
tones of 75 ms duration) that were randomly intermixed with deviant (p = 0.5) stimuli.
Stimulus onset asynchrony (SOA) was fixed at 500 ms. The deviant tones differed from
the standard tones in terms of frequency, duration, intensity, perceived location of
sound origin, or contained a silent gap in the middle of the tone (i.e. gap deviants). The
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deviants were 10% lower (composed of 450, 900, and 1350 Hz partials) and the other
half were 10% higher (composed of 550, 1100, and 1650 Hz partials). Half of the inten-
sity variants were at 80 dB and the other half at 60 dB. A change in perceived location
was created by creating an 800 μs time difference between the channels, leading to a
change in location of approximately 90°. Half of the deviants had a 800 μs delay in the
right channel while the other half was in the left channel. In the gap deviants 7 ms (in-
cluding a 1 ms rise and fall) were removed from the middle of the standard stimulus.
Three blocks of these stimulus sequences were presented for a total of 15 min (5535
stimuli). Each sequence started with a 15 standard tones, followed by a sequence in
which every second tone was a standard (p = 0.5) and every other tone was one of the
five deviants (p = 0.1 each). One deviant of each category was presented once every five
deviants. No two deviants were presented consecutively.Recordings
ERPs were recorded with a cap embedded with Ag+/Ag+Cl− electrodes (EasyCap,
Herrching-Brieibrunn, Germany) positioned on 8 scalp locations, including left, right,
and middle frontal (F3, F4, FZ); left, right, and middle central (C3, C4, CZ) and both
middle parietal (PZ) and occipital (OZ) sites, according to the 10–10 system. An elec-
trode on the nose served as reference and a ground electrode was positioned above the
FZ site. Electrodes were placed above and below the right eye to record vertical
electrooculographic (VEOG) activity and at the external canthus of both eyes to meas-
ure horizontal electrooculographic (HEOG) activity. Electrical recordings were carried
out using a Brain Vision V-8 Amp® (Brain Products GmbH, Munich, Germany) ampli-
fier and Brain Vision Recorder® (Brain Products GmbH, Munich, Germany) software.
Electrical activity was sampled at 500 Hz, with amplifier bandpass filters set at 0.1-
100.0 Hz. Electrode impedances were kept below 5 kΩ. Off-line analysis was performed
with Brain Vision Analyzer® software (Brain Products, GmbH, Munich, DE). For each
stimulus, electrical epochs of 500 ms duration (beginning 100 ms prior to stimulus on-
set) were digitally filtered (0.1-20 Hz) (Sabri & Campbell 2002), ocular (Gratton et al.
1983) and baseline corrected (relative to the pre-stimulus segment), and only epochs
with EEG voltages below 75 μV were used for final ERP averages, which were con-
structed separately for the standard and each deviant stimulus type at each electrode
site. Waveforms for the low and high frequency deviants, those for the low and high in-
tensity deviants, and those for the right and left location, were averaged together.
MMNs were analyzed with difference waveforms, which were derived by digital point-
by-point subtraction of the standard stimulus values from those elicited by each of the
deviant stimuli. Based on visual inspection of the grand average waveforms (i.e., aver-
aged across all participants), MMN amplitude was measured as the most negative peak
between 120–250 ms. MMN amplitude and latency (time to reach peak MMN) were
measured at the midline frontal site (FZ), within the region exhibiting maximal MMN
amplitude. Amplitude of the N1 component (peak negativity between 90–120 ms) elic-
ited by the standard stimulus was also measured (from FZ) to determine whether or
not MMN modulation by CDP-choline was associated with alterations in sensory
registration.
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Adverse events were evaluated by having participants complete a 5-point Likert scale
(0 = none, 4 = severe) on common symptoms (e.g., jitteriness, headache, nausea, vomit-
ing) associated with nicotinic stimulation (adapted from Harkrider and Hedrick 2005).Vitals
Heart rate (HR) (beats per minute [bpm]), systolic (SBP) and diastolic (DBP) blood pres-
sure (milliliters per milligram of mercury [ml/mgHg]) were measured before and after
gum chewing, with the participants in a sitting position. These measures were only used
for safety purposes.Analysis
Statistical analysis was carried out with the Statistical Package for Social Sciences (SPSS
Inc., Chicago, IL). In order to reduce Type I statistical errors, analyses was limited to
MMNs derived from frontal electrodes, where amplitude is maximal. In the primary
group-wise analyses with the entire sample (N = 24), the five deviant MMNs were
analyzed in separate repeated measures analysis of variance (ANOVA) with treatment
(3 levels: placebo, 500 mg, 1000 mg) and site (F3, FZ, F4) as within-subject factors. In
the secondary, exploratory analyses, separate mixed ANOVAs were carried out with the
5 deviant MMNs, with treatment and site as within-subject factors and group (3 levels:
low, medium and high amplitude MMN participants) as a between-subject factor.
Using placebo session data, groups were derived with respect to each of the 5 MMN
deviant types by ranking midline frontal (FZ) baseline (placebo) amplitudes of partici-
pants from the smallest to largest and designating the two groups of 8 individuals with
the extreme low and high amplitudes as the “low” and “high” groups, respectively. The
remaining 8 participants were designated as the “medium” group. This same stratifica-
tion procedure has been used in our previous work on nicotine and sensory gating
(Knott et al. 2013). The ANOVAs also included an examination of order effects, but
these were not evident with any of the study findings. Greenhouse-Geisser correction
was applied to within-subject factors with more than 2 levels and, regardless of whether
significance (p >0.05) was observed with main or interaction effects, follow-up compar-
isons (Bonferroni-corrected) were conducted to test a priori hypotheses. Of primary
interest in the exploratory analyses were the effects of treatment and group interaction
effects, testing significance of CDP-choline (vs. placebo) effects within each group. If
site was not involved in the interactions, comparisons were carried out with MMN
values at the frontal midline (FZ) site. Additional post-hoc analyses were also carried
out to further clarify the source of interaction effects. Adverse events and vital signs
were analyzed with similar mixed ANOVAs but without the site factor.
The use of placebo MMN scores in the exploratory analyses both for representing
the best point estimate of a given individuals ‘usual’ MMN (for subgrouping) and for
inclusion in the mixed ANOVA model possibly introduced a regression toward the
mean bias (Barnett et al. 2005) in the findings (e.g. an individual who exhibits a smaller
MMN in the low baseline group would be more likely to show a higher amplitude score
in the next session, even if no drug was administered in the session). Since regression
to the mean effects would be expected regardless of whether we segmented participants
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additional sets of mixed ANOVAs using the 500 mg and 1000 mg session data to sub-
group our participants.Results
Grand averaged raw midline (FZ, CZ, PZ) waveforms elicited by the 5 deviant and stand-
ard stimuli are shown in Figure 1, and grand average difference waveforms (deviant
waveform minus standard waveform) for each deviant are displayed in Figure 2, along
with the topographic distribution maps of peak MMN activity associated with each de-
viant type. Robust MMN components were elicited by all deviants, with maximum
amplitude being shown at frontal electrodes.
Figure 3 displays the grand averaged MMNs for each deviant in the 3 segmented groups.
In order to establish the presence of an MMN in the low baseline amplitude group, ampli-
tudes at FZ to all deviants in the placebo condition were compared to zero using a t-test.
Amplitudes and 2-tailed t-test statistics are summarized in Table 1. Except for the MMN
elicited by the gap deviant, MMN amplitudes for all deviants in the low baseline group
were significantly different from zero.Duration MMN
In the primary group-wise analysis, treatment effects were not significant but a site ef-
fect emerged [F, (2, 40) = 13.80, p < 0.001], with amplitudes at Fz > F4 > F3 (p < 0.05).
Analysis yielded significant group [F, (2, 21) = 11.01, p < 0.01] and group x treatment
interaction effects [F (4, 36) = 4.81, p < 0.005] for amplitude. Grand-average midfrontal
(FZ) difference waveforms for each deviant and treatment, in each group are shown inFigure 1 Grand averaged unsubtracted waveforms for all participants for the standard and each
deviant stimulus during placebo treatment.
Figure 2 Grand averaged waveforms (a) and their scalp voltage distributions (b) for all participants
for each deviant in the placebo session.
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nificantly larger MMNs with the 500 mg (p < 0.01) and 1000 mg dose of CDP-choline
(p < 0.05) compared to placebo. No significant treatment differences were observed in
the medium baseline amplitude group, but in the high baseline amplitude group both
500 mg (p < 0.05) and 1000 mg CDP-choline doses (p < 0.01) produced significantly
smaller MMNs compared to placebo.
Post-hoc comparisons showed all groups differed from each other in the placebo ses-
sion (p < 0.01), and while only medium and high baseline amplitude groups were sig-
nificantly different in the 500 mg dose session (p < 0.05), none of the groups differed
from each other in the 1000 mg dose session.Figure 3 Grand averaged subtracted MMN waveforms (at Fz) of low, medium and high amplitude
groups for each deviant during placebo treatment.
Table 1 Mean MMN amplitudes (±SE) at FZ plus t-statistic and significance values
resulting from 2-tailed comparison of means against zero for all placebo derived
deviants in the low amplitude group
Deviant Mean amplitude (±SE) t value Significance
Duration −0.67 μV (0.54) −3.53 p = .010
Frequency −1.18 μV (1.09) −3.05 p = .019
Gap 0.95 μV (0.78) 0.35 p = .740
Intensity −1.48 μV (1.15) −3.64 p = .008
Location −1.01 μV (0.91) −3.14 p = .016
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Group-wise analysis yielded no treatment effects, but site was significant [F (2, 42) =
5.04, p < 0.02], with amplitudes at Fz > F4 > F3 (p < 0.05).
Amplitude analysis resulted in a significant group [F (2.21) = 8.28 (p < 0.003] effect
and a non-significant trend for a group x treatment interaction [F = (4, 36) = 2.39,
p < 0.08]. As shown in Figure 4, treatment comparisons failed to show any CDP-
choline effects in either low or medium baseline amplitude groups, but MMNs were
significantly reduced in the high baseline amplitude group with the 500 mg dose
compared to placebo (p < 0.05).
Groups were significantly different from each other in the placebo session (p < 0.01)
but not during the two active treatment sessions.
No significant effects were observed for MMN latency.Gap MMN
Group-wise analysis did not show a treatment effect but site was significant [F (2, 42) =
12.57, p < 0.001], with amplitudes at Fz > F4 > F3 (p < 0.05).
MMN elicited by the gap deviants was affected by group [F (2,21) = 23.89, p < .001]
and a group x treatment interaction [F (4, 36) = 3.02, p < 0.05]. Shown in Figure 4, treat-
ment comparisons within each group showed a trend for the 500 mg dose to increase
MMN in the low baseline amplitude group (p < 0.08), while in the high baseline ampli-
tude group MMN reduction was seen with the 500 mg dose (p < 0.05) and approached
significance with the 1000 mg dose (p < 0.06).
All groups were significantly different from each other in the placebo (p < 0.05) and
1000 mg dose session (p < 0.05) but while amplitudes of the low baseline group were
significantly smaller than those of the medium and high baseline groups during the
500 mg dose session (p < 0.05), they were similar in the medium and high baseline
groups. No group, treatment or interaction effects were observed for MMN latency.Intensity MMN
Group-wise analysis showed no treatment effect but site was significant [F (2, 42) =
12.48, p < 0.001], with amplitudes at Fz > F4 > F3 (p < 0.05).
Group [F (2,21) = 4.47, p ¸0.03] and group x treatment interaction effects [F (4, 36) =
4.92, p < 0.04] were found for intensity MMN. As displayed in Figure 4, treatment
Figure 4 Grand averaged MMN waveforms (at Fz) displaying treatment differences by deviant and
by baseline (placebo) grouping.
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significantly larger MMNs than placebo (p < 0.01) and a similar, non-significant trend
(p < 0.06) was shown with the 1000 mg dose compared to placebo. The medium base-
line group failed to exhibit any significant treatment effects but in the high baseline
amplitude group MMN was attenuated (vs. placebo) with both 500 mg (p < 0.01) and
1000 mg doses (p < 0.006).
Post-hoc comparisons showed groups to be significantly different from each other
during placebo (p < 0.01) but not during the 500 mg or 1000 mg treatment sessions.
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Location MMN
No treatment effect was found with group-wise analysis but a significant site effect was
shown [F (2, 42) = 9.95, p < 0.001], with amplitudes at Fz > F4 > F3 (p < 0.05).
The location MMN amplitudes were significantly altered by group [F (2,21) = 7.60,
p < 0.01] and group x treatment interaction effects [F (4, 36) = 4.56, p < 0.05]. As ob-
served in the low baseline amplitude group (Figure 4), treatment comparisons showed
significant (vs. placebo) MMN amplitude increases with the 500 mg dose (p < 0.05) and
a similar but non-significant trend for MMN amplitude increases with the 1000 mg
dose (p < 0.08). CDP-choline exerted opposite effects in the medium and high baseline
amplitude groups, with the 500 mg reducing MMN compared to placebo (p < 0.05).
Group amplitudes were significantly different from each other during placebo treat-
ment (p < 0.05) but not during CDP-choline treatment.
MMN latency analysis did not yield any significant main or interaction effects.
Standard N1
CDP-choline did not exert any significant effects on NI amplitude or latency.
Additional analyses
For the mixed ANOVAs conducted with subgroups formed with the 500 mg session
data and the 1000 mg session data, significant group differences, as shown in the pri-
mary analysis, were observed for the different deviants but no significant treatment or
group x treatment interactions were found.
Adverse symptoms
There were no serious adverse events associated with CDP-choline and no adverse
events led to discontinuation by any of the participants. Analysis did not yield any sig-
nificant treatment differences in self-reported adverse reactions.
Vitals
No significant differences were observed between placebo and CDP-choline doses with
respect to heart rate or blood pressure measures.
Discussion
There were no significant whole group effects with CDP-choline but exploratory analysis
showed individual differences in MMN response to the acute choline agonist challenge.
Our findings with CDP-choline underscore previous reports of individual variability in
sensory and cognitive response to nicotine and they extend these observations to the
modulating effects of a choline supplement on auditory deviance detection, a pre-
attentive sensory process which is commonly impaired in SZ. Depending on treatment
dose, initial amplitude, and deviant type, deviance detection was shown to be enhanced,
suppressed or insensitive to modulations of choline, which among its other properties, ex-
erts agonist actions at α7 receptors. These findings add some support to the use of a “test
dose” design in healthy surrogates, aided by specific biomarkers predicting and assessing
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agents for SZ cognition (Chou et al. 2012; Koychev et al. 2012).
Improvement in acoustic change detection with CDP-choline, in the absence of
changes in obligatory sensory registration indexed by the NI ERP, was shown in individ-
uals with relatively diminished neural response (MMN) to auditory deviants, while in
those with optimal or supraoptimal responses, a reduction in change detection was evi-
denced with this acute α7 agonist treatment. In general, the findings parallel our earlier
report of the dual actions of the broad spectrum nAChR agonist, nicotine, on MMN in
groups of healthy surrogates exhibiting relatively compromised and efficient deviance
detection (Knott et al. 2014). Increases in auditory change detection in individuals with
diminished MMNs are of particular importance for SZ. Additionally, as these effects
were shown in nonsmokers, the gains with CDP-choline reflect a true enhancement of
a suboptimal sensory level process and are not simply reflecting a “normalization” or
“remediation” of a sensory deficiency that may accompany the more general disturb-
ance of cognitive neural networks seen during smoking/nicotine withdrawal in chronic
smokers (Beaver et al. 2011; Cole et al. 2010).
The observation that both the augmenting and suppressing effects of CDP-choline on
auditory change detection in the biomarker-defined subgroups were deviant dependent
generally mirrors the baseline-dependent effects of nicotine reported in neuropsychi-
atric disorders, with those exhibiting the most impaired cognition in select domains
evidencing the greatest improvement with nicotine (Morisano et al. 2013; Newhouse
et al. 2004; Perkins 1999). Although non-significant dose-related trend effects were
observed with some deviants (gap, intensity), CDP-choline in general was able to both
increase (in low amplitude individuals) and decrease MMN (in high amplitude individ-
uals) elicited by duration, intensity and location deviants. The MMN elicited by the fre-
quency deviant was only attenuated, and not increased by CDP-choline, and this was
shown in the high amplitude group. Gap-deviant MMN was not affected by the choline
supplement, an effect which may in part be related to measurement variability as the
MMN in the low amplitude group was relatively undetectable in the placebo and drug
conditions.
The number, location, and roles of cortical MMN generators remains unresolved
(Tata and Ward 2005) but neuroimaging evidence to date has implicated a temporo-
frontal network, with MMN and functional magnetic resonance imaging (fMRI) BOLD
responses elicited by changes in regularity of different elemental auditory features being
generated in separate loci of the superior temporal gyrus (Alho et al. 2013; Näätänen
et al. 2011). The two distinct processes thought to be involved in auditory change de-
tection, including a “sensory” mechanism (detects a deviant sound on the basis of dif-
ferential refractoriness of neural populations sensitive to the standard and deviant
sounds) and a “cognitive” mechanism (reveals deviance by comparing incoming audi-
tory information with a template derived by previous input), also seem to be anatomic-
ally separate, with the former involving primary auditory areas, while the latter involves
secondary auditory areas (Szycik et al. 2013). Differential sensitivity of auditory deviants
to CDP-choline may reflect the variable distribution of neuronal α7 nAChRs, which are
heavily expressed in the primary auditory cortex and are integral to its structural and
functional development (Ji and Suga 2008; Soto et al. 2006). In similar stratified sub-
groups, the deviance-dependent nicotine effects on MMN were shown to be slightly
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pression were not apparent with the same deviant type (i.e., nicotine either increased or
decreased detection of specific auditory deviants), possibly reflecting regional differ-
ences in the number of non-α7 nicotinic receptors.
Although directly enhancing signal processing in primary sensory regions (Sarter and
Bruno 1997), the diffuse cholinergic input system extends to the frontal cortex where it
can trigger complex patterns of recruitment of cholinergic modules that project to
sensory and sensory-associated cortical regions to enhance the detection and process-
ing of stimuli of a particular modality (Gatmayo et al. 2003; Nelson et al. 2005). Nico-
tinic receptor stimulation modulates the release of multiple neurotransmitters, and
enhances tone-evoked physiological responsivity in the auditory cortex via activation
of NMDA receptor-mediated glutamatergic neurotransmission (Flores-Hernandez
et al. 2009; Konradsson-Geuken et al. 2009; Levy and Aoki 2002; Liang et al. 2008;
Metherate and Hsieh 2003; Metherate 2004; Yang et al. 2013). nAChRs are abun-
dantly expressed in the prefrontal cortex (PFC) and play a key role in the regulation
of complex cognitive processes (Wallace and Bertrand 2013b). Studies of MMN
source localization point to a role for the frontal cortex, where α7 subunit receptors
are found to be highly prominent in the postsynaptic density of glutamatergic synap-
ses and are thought to provide the depolarization necessary for NMDA receptor
neurotransmission (Yang et al. 2013). The ability of CDP-choline to modulate MMN
in a manner that varies between individuals and deviant types may result from the
coordinated interplay of α7 nAChR modulated NMDA sensory and higher cortical
circuits, with each region varying inter-individually both in its participation in fea-
ture specific auditory change detection and its regulation by α7-nicotinic and gluta-
matergic signaling.
Dose differences emerged with CDP-choline, with MMN being affected most often
with the lower (500 mg) dose. Depending on the feature change, significant alterations
in MMN seen with 500 mg were sometimes observed with the 1000 mg dose (duration-
and intensity-deviant MMN), with the direction and degree of MMN change being
similar across doses. Depending on the individual’s amplitude, the same dose was able
to increase and decrease neural responses to auditory deviants, CDP-choline generally
acting to increase MMN in the low amplitude group while decreasing MMN in the
higher amplitude group. Observed across the neuroimaging literature, the pattern of
neural response induced by cholinergic modulation often resembles an inverted
U-shaped function that depends upon the level of regional activation prior to drug
challenge (Bentley et al. 2011). Hence, enhanced regional activity is most readily ob-
served with pro-cholinergic drugs when such activity is relatively low under placebo,
but decreased activity is seen when regional activation is high to begin with (e.g. Thiel
et al. 2005). A similar type of inverted-U response is seen when comparing subject
types, with pro-cholinergic drugs normalizing task/stimulus-evoked activations in indi-
viduals who, because of aging-, disease- or genetic-related factors, exhibit abnormally
low or high activation, while in individuals with normal activation patterns studies
show either no modulation or a reverse pattern of modulation in the same region and
with the same task/stimulus paradigm (Bentley et al. 2011).
MMN increases with CDP-choline were most frequently observed with the low dose.
Pro-cognitive effects of low and ultra-low doses of α7 agonists have been reported in
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clear, these low concentration agonists are described as ‘co-agonists’ as they have been
shown to facilitate receptor activation and enhance the acetylcholine-evoked current
without provoking receptor desensitization (Castner et al. 2011; Prickaerts et al. 2012;
Wallace and Bertrand 2013a). As microdialysis studies have shown that α7 receptor ag-
onists can directly increase glutamate (Gioanni et al. 1999) and dopamine levels in the
prefrontal cortex (Livingstone et al. 2009; Sydserff et al. 2009), improved deviance de-
tection indexed by frontal MMN increases with low dose CDP-choline may be achieved
through multiple mechanisms.
Possibly related to individual differences in the number and sensitivity of α7 nAChRs,
diminished auditory change detection characterizing the low baseline amplitude group
may be due to a relatively hypo-cholinergic state within sensory (auditory) cortex, while
efficient detection of auditory change may reflect an optimal cholinergic tone. Conse-
quently, the lower tonic cholinergic activity and decreased stimulus discriminability in
the low baseline group allows for a greater dynamic range of response secondary to
pro-cholinergic stimulation with CDP-choline, resulting in increased MMNs. By con-
trast, α7 agonist stimulation with CDP-choline in the high amplitude group may have
pushed these participants towards a hyper-cholinergic state relative to what they are ac-
customed to, and while this enhances sensory cortex activation, concomitantly it results
in reductions in selectivity to stimulus features and attributes (Bentley et al. 2011; Kuo
et al. 2009; Zinke et al. 2006). Meta-analyses of imaging studies using magnetic reson-
ance spectroscopy to quantify neurometabolites have shown reduced hippocampal cho-
line (expressed as choline/creatine ratio) levels in SZ (Kraguljac et al. 2012) and it is
possible that variability in endogenous brain choline may underly individual differences
in normal deviance processing. Also of potential relevance to these findings of individ-
ual differences in response to CDP-choline is the choline uptake transporter (CHT),
which imports choline from extracellular space to presynaptic terminals for use in nor-
mal acetylcholine synthesis/cholinergic transmission (Sarter and Parikh 2005). As CHT
capacity has been associated with variability in cognitive functioning (Sarter and Parikh
2009), and as human CHT gene polymorphisms have been associated with individual
differences in cortico-limbic activation (Neumann et al. 2006) and attentional process-
ing (Berry et al. 2014), genetic differences in CHT capacity may underly some of the
inter-individual variability in acoustic change detection response to CDP-choline.Limitations
Our findings are preliminary and are in need of replication with larger samples. These
data can be considered an incremental advancement in the current state of knowledge on
choline agonism - sensory processing relationships with caveats of: 1) lack of real plasma-
based biomarkers of endogenous choline availability; 2) no effort to control for covariates
affecting choline activity or MMN, and 3) obviously, no SZ patients were studied.
Although the recruitment of healthy volunteers can be considered a strength in that it
reduced the potential confounding effects associated with clinical trials in patients (e.g.
medication, disease chronicity), acute CDP-choline test-dose challenge studies are re-
quired in medicated patients prior to full phase II trials. Nonsmokers were targeted to en-
sure that any benefits gained with CDP-choline could not be attributed simply to a
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tested with nicotinic agents. Although nonsmoking patients are frequently used in early
phase trials (e.g. Koike et al. 2005; Olincy et al. 2006), SZ smokers and nonsmokers have
differed in their response to nicotine and α7 agonists (Lieberman et al. 2013) and com-
parison of their acute response to CDP-choline would inform future investigations. The
dose levels were limited and may have included lower (250 mg) and higher (2000 mg)
doses for a more complete dose–response profile, and future studies might repeat dosing
in closely spaced sessions to examine issues related to receptor desensitization. Collection
of choline plasma levels would also be useful in data interpretation. Our subgroups were
based on placebo data, which was also included in the statistical analyses. It is possible
that a ‘regression to the mean’ effect (arising from the fact that [low] deviance detection
could only improve, and ceiling [high] deviance detection only deteriorate) may have con-
tributed to the study findings, but the extent of this contribution is unclear and several
factors do not convincingly support a strong role in that: a) with counterbalancing (see
Analysis section), placebo was relatively equally distributed across the three sessions, thus
substantially attenuating a regression to the mean effect; b) regression to the mean effects
would be expected to be consistently shown with all deviant types and both doses but this
was not the case and c) our additional set of mixed ANOVAs using the low or moderate
dose session data to segment our groups did not result in any group x treatment interac-
tions. From this analysis we can tentatively conclude that CDP-choline effects in our
placebo-based MMN subgroups do not reflect a significant regression to the mean influ-
ence. However, reducing regression to the mean influences in future studies can be ac-
complished by selecting MMN subgroups from a larger sample, or study participants
could undergo an additional ‘pre-selective’ session, the data from which would be used to
stratify participants into subgroups but not for statistical analysis. MMN recordings were
not taken from mastoid sites, which would have allowed for a more specific interpretation
of CDP-choline effects on sensory processing at sites more proximal to the auditory cor-
tex. Given the contribution of sensory level processing to higher order mental operations
(Javitt 2000), neuropsychological testing accompanying the ERPs would help us to under-
stand the cognitive implications of choline modulated sensory processing. Moreover, add-
itional studies are required to assess whether sensory and/or cognitive mechanisms of
auditory deviance detection are impacted by cholinergic stimulation. As nAChRs are
found throughout midbrain and brainstem tracts of the auditory pathway (Habbicht and
Vater 1996; Happe and Morley 1998; Happe and Morley 2004; Morley 2005), both regions
being shown to display deviance detection properties (Escera et al. 2013), the use of early
latency ERPs components (<100 ms) may be important in mapping the extent to which
α7 receptor modulation affects deviance processing along the auditory hierarchy.Conclusion
Sensory and cognitive impairments are core features of SZ involving α7 nAChRs, which
are considered potential therapeutic targets for new treatments. Using the MMN, one
of the few biomarkers which can be reliably applied in translational research and drug
development studies (Todd et al. 2013), acute α7 agonist treatment with the dietary
supplement CDP-choline did not show any significant effects in our sample as a whole,
but was shown to positively influence deviance detection in a surrogate subgroup
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uals exhibiting optimal deviance detection. Although these preliminary findings need
replication and extension to other surrogate populations (e.g. schizotypal personality),
the modulating low dose effects of CDP-choline on auditory change detection indexed
with the translational biomarker MMN support further study of α7 receptor agonism
as a potential sensory enhancing mechanism in patients with schizophrenia.
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